Tuberous Sclerosis Complex (TS) affects about 1 in 6000/10,000 persons in the population, with 1 to 2 million people affected world-wide. TS is a congenital genetic disease that affects a number of organs. It is characterized by skin abnormalities and birthmarks, tuber-like growths in the eyes, the brain, and other internal organs, and varying severity of epilepsy and mental retardation. There is no cure, but treatment is available for some of the symptoms.
WHEN:
Wednesday December 3, 2003
3:00 pm
WHERE: Jeanne Timmins Amphitheatre (follow the signs from the main entrance) Montreal Neurological Institute and Hospital 3801 University Street (Parking is limited, you may park in front of the Royal Victoria on Pine Ave or at the top of University Street)
WHO:
Dr. Eva Andermann
Director of Neurogenetics, Montreal Neurological Institute and Hospital, Montreal, Canada
Dr. Fred Andermann
Director of Epilepsy Service, Montreal Neurological Institute and Hospital, Montreal, Canada
Dr. Alexis Arzimanoglou
Head, Epilepsy Program, Hôpital Robert Debré, Paris, France
Ms Nancy Bryce
Vice-President & Director of Education, Research and Development Tuberosis Sclerosis Canada sclérose tubereuse
Mr. Ron Hutchison
Board Member, Tuberosis Sclerosis Canada sclérose tubereuse
Dr. Philippe Ryvlin
Professor of Neurology, University of Lyon, France
For more information please contact:
Sandra McPherson, Montreal Neurological Institute Tel: 514-398-1902,
Email: sandra.mcpherson@mcgill.ca
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.